LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Inside the First MSK CEO Summit
Company News

Inside the First MSK CEO Summit

By TJ HalvorsonNovember 19, 2026 6 min read Premium comments

Advertisement

Inside the First MSK CEO Summit
Created by Orthopedics This Week

On Monday, November 9, thirty chief executives from across the musculoskeletal industry met at the Hermosa Inn in Paradise Valley, Arizona, next door to Scottsdale, for the first MSK CEO Summit. There was no stage, no panels and no sponsors in the room. The program was a single day of conversation among peers, held under confidentiality ground rules so that people could speak plainly.

The Summit was organized by Drue De Angelis, Managing Partner of The De Angelis Group, a retained executive search firm that works exclusively in MSK. Sixty-five CEOs applied for the thirty seats.

"The candor and engagement in that room was like nothing I've witnessed in nearly 40 years in the orthopedic industry," De Angelis said.

How the day worked

The group gathered for a reception on Sunday evening and spent Monday moving between two formats. Town halls put all thirty CEOs in one room. Round tables split them into three cohorts by company stage, Anchor, Builder and Emerging, so that each CEO also spent time in a group of about ten with peers facing problems of the same scale.

The size is deliberate. The Summit is kept to thirty CEOs to maintain intimacy and to give every person in the room the opportunity to be engaged. There are no observers, only participants.

De Angelis served as emcee and led the town halls alongside three moderators: David Dvorak, former CEO of Zimmer Biomet, Jerry DeVries of DeVries Capital, and Kevin Rocco, who founded and sold Biorez. The moderators also guided the cohort round tables.

De Angelis opened the first town hall with the premise behind the whole event: "No CEO can do it alone." He also told the group what he wanted them to leave with. "I hope that out of this meeting you walk away with some new relationships that are meaningful, and that you'll continue to pursue those."

What the CEOs talked about

The Summit ran under the Chatham House Rule: what was said can be shared, but not who said it. The lines quoted in this section come from the room and are left unattributed for that reason.

Talent and culture opened the day. The discussion centered on hiring for the stage a company is actually in, since early teams need people who can cover broad ground before the company can afford specialists. "When you're a startup, you have to use all of the levers," one CEO said. "You can't compete on cash." The mistake raised most often was waiting too long for a weak fit to improve. As one voice in the room put it, "Hope isn't a great strategy."

On culture, the room kept returning to one idea: culture is what leaders do, not what they post on the wall. "Culture is not just a meeting with words; it's how you act," one CEO said. Another was blunter: "Culture reflects leadership." One founder described the lesson this way: "Be more human with your people. This is not their entire life. This might be my entire life." Remote work drew real disagreement. The group did not settle whether culture can be built at a distance, but it did agree that distributed teams need deliberate, frequent contact.

Advertisement

Boards and investors came next. CEOs compared how they choose capital and how they prepare directors, including the discipline of knowing how a vote will go before the meeting starts. One CEO described the order of every board update: "I like to lead with what the challenges have been, and then talk about the successes."

Differentiation and pricing ran through the afternoon. Pricing pressure moves in one direction while costs rise. "Innovation is the obvious solution," one CEO said. Without it, "you're just a commodity. It's a race to the bottom."

Clinical evidence, reimbursement and market access were treated as one linked problem. "Clinical evidence is a portion of it," one participant said. "We're talking trust." The group questioned whether evidence was essential to commercial success. On reimbursement, one CEO was direct: "You fight for a code, and there's no guarantees." Market access was described as a business model question more than a scientific one.

Capital closed the program. "There is money out there. It's hard to find," one CEO said. The shared view was that the financing method has to match the company's stage, and that existing investors deserve regular attention even while a CEO is chasing new ones.

One of the last comments from the floor returned to where the day began, with people. "I've seen companies that have great technology with the wrong people leading it," a CEO said. "You can take a mediocre product, put an absolute killer team on it, and they will succeed."

In their words

The reaction started before the day ended. In the hallway between sessions, one CEO said, "You can't get this anywhere else." Another said the walls came down almost immediately. Afterward, several CEOs volunteered a few words on the record, and they said much the same.

"CEOs of early, mid, and later stage companies explored topics spanning talent, culture, market access, financing, and industry stewardship. In a safe environment, there was a lot of transparency, vulnerability, and learning."

Stuart Simpson, CEO, THINK Surgical

"The conversations were candid and useful, and the room had the right mix of operators, founders and veterans. As a growing business who still runs in founders mode, I took away great insight on how to build an organization for scale. The topics covered wouldn't be possible in any other gathering, and I loved being able to continue the conversation long after the 'formal' meeting ended."

Ashesh Shah, Maxx Orthopedics

"It was a unique and valuable opportunity to connect with fellow MedTech CEOs, share perspectives and experiences, and learn from one another. I appreciated the shared commitment in the room to helping each other become better leaders and stewards of the companies we lead."

Advertisement

Jamal Rushdy, CEO, Miach Orthopaedics

"In my 35-plus years in MSK, I've heard of many of these leaders, and it was a real privilege to finally meet so many of them, and to reconnect with four great friends I've worked with directly over the years. The openness in the room made it easy to share some of my own experiences, good and bad, and to learn from everyone else's."

Chris Hughes, Founder, Chairman & CEO, OsteoRemedies

"One of the best experiences I've had getting CEOs from all stages of medical device companies in one room together to discuss common challenges, strategize best practices, and commiserate."

Robert Isaacs, TrackX Technologies

What comes next

De Angelis closed the final town hall by telling the group what had surprised him. "I thought this was going to be a bunch of people keeping their cards close, but I've seen cards laid face up on the table, which is super unusual," he said. "We see each other at meetings, and we each have our jersey on. You're on this team, you're on that team. But here something different happened. We're all fighting the same battles."

Each CEO left with a challenge coin. "This coin is to memorialize this experience. It is a closed circle," De Angelis told them, "and that is what to keep in mind about who said what as you walk away from this experience." The day ended with dinner on the patio.

Every attendee has been asked for candid feedback through a post-event survey, and those responses will shape the next edition. De Angelis plans to hold the Summit again and to keep it the same size. The date and venue have not been announced.

Seats are limited and awarded through a careful selection process by size and specialty. CEOs of MSK companies can learn more at mskceo.com.

"If you attend one event a year, this should be it! This is my new MUST ATTEND event of the year (I was lucky enough to be among the chosen few)! It's a raw, real, and vital source of truth in a complex and challenging landscape. The format is thoughtfully engaging and inspiringly candid and intimate. There is no other peer engagement environment like it anywhere."

Marc Viscogliosi, VB Spine

Author

TH
TJ Halvorson

The De Angelis Group | Orthopedics This Week | MSK Innovations

Why This Matters

Two Perspectives

MBA Lens: Economic and industry impact

The inaugural MSK CEO Summit convened thirty executives for confidential peer discussions on critical industry challenges. Topics included talent acquisition, culture development, board and investor relations, market differentiation, and navigating pricing pressures. The event fostered candid conversations on company strategy, market access, and capital raising, emphasizing the shared battles faced by leaders across the musculoskeletal sector.

  • Innovation is crucial for differentiation in a market facing pricing pressure and rising costs, to avoid becoming a commodity.
  • Market access is primarily a business model challenge, with clinical evidence and reimbursement codes offering no guarantees for commercial success.

PhD Lens: Clinical and outcomes impact

The first MSK CEO Summit gathered industry leaders for confidential discussions, where the role of clinical evidence in commercial success was a key topic. Participants questioned whether evidence alone was sufficient for market adoption, highlighting that "trust" and strategic market access considerations are equally vital alongside scientific data. The format allowed for frank exchange on these complex issues.

  • Clinical evidence is a component of market access, but its direct correlation to commercial success was questioned, with "trust" identified as a significant factor.
  • Securing reimbursement codes and achieving market access was described as a complex business model challenge, not solely a scientific validation issue.
React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy